Business
Ernexa Therapeutics Inc.: Loss of this license or termination of the Factor L&C Agreement could significantly harm our product development and ability to enter co-development strategic partnerships, materially impacting our business.
Revenue increased 0.0% to $582.0K, while Net income increased 68.4% to ($14.1M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $582.0KWatch
- Profitability — Net income ($14.1M)Watch
- Cash generation — Free cash flow ($7.1M)Note
- Accounting — Formula distress score · manipulation screen not computed · earnings quality weakWatch
- Insiders — 1 buys; 0 sells in 365 daysOK
- Capital — Comparable payout data unavailableNote
Leadership changes
From Ernexa Therapeutics Inc.'s own filings, the day they're filed.
- Sandra Gurrola · President · departureeff. 2026-07-03
- Elena Ratner · Director · appointmenteff. 2025-01-07
- Dorothy Clarke · Directors · departureeff. 2025-01-03
Latest filings
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-07-02
- 8-K · Company announcement2026-07-02
- 8-K · Company announcement2026-06-26
- 10-Q · Quarterly report2026-05-11
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Ernexa Therapeutics Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.